The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Lactobacillus casei
Probiotics
Type 2 diabetes mellitus
Journal
Iranian biomedical journal
ISSN: 2008-823X
Titre abrégé: Iran Biomed J
Pays: Iran
ID NLM: 9814853
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
entrez:
28
5
2018
pubmed:
29
5
2018
medline:
26
2
2019
Statut:
ppublish
Résumé
Type 2 diabetes mellitus (T2DM) is related to the gut microbiota with numerous molecular mechanisms. Modulating the gut microbiota by probiotics could be effective in management of T2DM. The aim of the present trial was to evaluate the effect of Lactobacillus casei on glycemic control and serum sirtuin1 (SIRT1) and fetuin-A in patients with T2DM. Forty patients with T2DM (n = 20 for each group) were divided into intervention (probiotic) and placebo groups. The intervention group received a daily capsule containing 108 cfu of L. casei for eight weeks. The patients in placebo group took capsules containing maltodextrin for the same time duration. Anthropometric measurements, dietary intake questionnaires, and blood samples were collected, and the patients were assessed by an endocrinologist at the beginning and at the end of the trial. Fasting blood sugar, insulin concentration, and insulin resistance significantly decreased in probiotic group compared with placebo group (-28.32 [-50.23 to -6.41], 0.013; -3.12 [-5.90 to -0.35], 0.028; -32.31 [-55.09 to -9.54], 0.007, respectively). Moreover, HbA1c reduced after intervention, but the reduction was not significant (-0.45 [-0.96 to 0.05], 0.077). In comparison with placebo, the L. casei supplementation significantly increased SIRT1 and decreased fetuin-A levels at the end of the trial (0.52 [0.026 to 1.02], 0.040; -17.56 [-32.54 to -2.58], 0.023, respectively). L. casei supplementation affected SIRT1 and fetuin-A levels in a way that improved glycemic response in subjects with T2DM. Affecting the SIRT1 and fetuin-A levels introduces a new known mechanism of probiotic action in diabetes management.
Sections du résumé
Background
Type 2 diabetes mellitus (T2DM) is related to the gut microbiota with numerous molecular mechanisms. Modulating the gut microbiota by probiotics could be effective in management of T2DM. The aim of the present trial was to evaluate the effect of Lactobacillus casei on glycemic control and serum sirtuin1 (SIRT1) and fetuin-A in patients with T2DM.
Methods
Forty patients with T2DM (n = 20 for each group) were divided into intervention (probiotic) and placebo groups. The intervention group received a daily capsule containing 108 cfu of L. casei for eight weeks. The patients in placebo group took capsules containing maltodextrin for the same time duration. Anthropometric measurements, dietary intake questionnaires, and blood samples were collected, and the patients were assessed by an endocrinologist at the beginning and at the end of the trial.
Results
Fasting blood sugar, insulin concentration, and insulin resistance significantly decreased in probiotic group compared with placebo group (-28.32 [-50.23 to -6.41], 0.013; -3.12 [-5.90 to -0.35], 0.028; -32.31 [-55.09 to -9.54], 0.007, respectively). Moreover, HbA1c reduced after intervention, but the reduction was not significant (-0.45 [-0.96 to 0.05], 0.077). In comparison with placebo, the L. casei supplementation significantly increased SIRT1 and decreased fetuin-A levels at the end of the trial (0.52 [0.026 to 1.02], 0.040; -17.56 [-32.54 to -2.58], 0.023, respectively).
Conclusion
L. casei supplementation affected SIRT1 and fetuin-A levels in a way that improved glycemic response in subjects with T2DM. Affecting the SIRT1 and fetuin-A levels introduces a new known mechanism of probiotic action in diabetes management.
Substances chimiques
alpha-2-HS-Glycoprotein
0
Sirtuin 1
EC 3.5.1.-
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
68-77Références
J Agric Food Chem. 1999 Apr;47(4):1460-6
pubmed: 10563999
Mol Cell Endocrinol. 2000 Jun;164(1-2):87-98
pubmed: 11026561
Cell Signal. 2001 Feb;13(2):85-94
pubmed: 11257452
Gastroenterology. 2001 Sep;121(3):580-91
pubmed: 11522742
Diabetes. 2002 Aug;51(8):2450-8
pubmed: 12145157
Circulation. 2006 Apr 11;113(14):1760-7
pubmed: 16567568
Nutrition. 2007 Jan;23(1):62-8
pubmed: 17084593
Cell. 2006 Dec 15;127(6):1109-22
pubmed: 17112576
J Clin Invest. 2007 Jan;117(1):24-32
pubmed: 17200703
Diabetologia. 2007 Nov;50(11):2374-83
pubmed: 17823788
Nature. 2007 Nov 29;450(7170):712-6
pubmed: 18046409
Genes Dev. 2008 Jul 1;22(13):1753-7
pubmed: 18550784
Diabetes. 2008 Oct;57(10):2762-7
pubmed: 18633113
Eur J Drug Metab Pharmacokinet. 2008 Apr-Jun;33(2):101-6
pubmed: 18777945
Br J Nutr. 2009 Jun;101(11):1679-87
pubmed: 19017418
J Appl Microbiol. 2009 Nov;107(5):1681-6
pubmed: 19457033
Vopr Pitan. 2009;78(2):18-23
pubmed: 19514338
Trends Endocrinol Metab. 2009 Sep;20(7):325-31
pubmed: 19713122
Int J Mol Sci. 2009 Aug 27;10(9):3755-75
pubmed: 19865517
Eur J Clin Nutr. 2010 Jun;64(6):636-43
pubmed: 20216555
J Clin Endocrinol Metab. 2010 Nov;95(11):4877-81
pubmed: 20660040
Br J Nutr. 2010 Dec;104(12):1831-8
pubmed: 20815975
Nat Rev Cancer. 2010 Dec;10(12):819-23
pubmed: 21102633
Nutrition. 2012 May;28(5):539-43
pubmed: 22129852
Benef Microbes. 2011 Dec 1;2(4):295-303
pubmed: 22146689
Eur J Endocrinol. 2012 Mar;166(3):503-10
pubmed: 22170794
Lipids Health Dis. 2012 Feb 22;11:29
pubmed: 22356933
PLoS One. 2012;7(6):e39748
pubmed: 22768116
Clin Endocrinol (Oxf). 2013 Sep;79(3):356-63
pubmed: 23067229
Mol Aspects Med. 2013 Feb;34(1):39-58
pubmed: 23159341
Arch Med Sci. 2012 Nov 9;8(5):826-33
pubmed: 23185191
J Biol Chem. 2013 Aug 30;288(35):25088-97
pubmed: 23836895
Ann Nutr Metab. 2013;63(1-2):1-9
pubmed: 23899653
Br J Nutr. 2014 Feb;111(4):598-605
pubmed: 24001238
World J Diabetes. 2014 Dec 15;5(6):894-900
pubmed: 25512793
Iran J Public Health. 2015 Feb;44(2):228-37
pubmed: 25905057
Obes Surg. 2016 Jun;26(6):1215-20
pubmed: 26337692
Nutr Metab (Lond). 2016 Feb 20;13:14
pubmed: 26900391
Medicina (Kaunas). 2016;52(1):28-34
pubmed: 26987497
Eur J Nutr. 2017 Jun;56(4):1535-1550
pubmed: 26988693
Medicine (Baltimore). 2016 Jun;95(26):e4088
pubmed: 27368052
Curr Diabetes Rev. 2017;13(6):582-589
pubmed: 27758705
Int J Vitam Nutr Res. 2016 Jun;86(3-4):215-227
pubmed: 28436760
Med Sci Monit. 2017 Jun 22;23:3044-3053
pubmed: 28638006
Diabetes Metab Syndr. 2018 Sep;12(5):617-624
pubmed: 29661605
Mol Endocrinol. 1993 Nov;7(11):1445-55
pubmed: 7906861